Healthcare
Quote through 2026-08-05T13:30:00Z · Stale
Quote synced 2026-08-05T23:26:01.943256Z
Daily bars through 2026-08-04 · Delayed
Daily bars synced 2026-08-05T04:43:34.989679Z
Fundamentals through 2025-10-31 · Stale
Fundamentals synced 2026-08-05T22:39:51.787625Z
Forecasts: Stale
Forecasts synced 2026-05-05T11:53:49.765898Z
Ownership through 2025-10-31 · Stale
Ownership synced 2026-08-05T22:39:51.787625Z
Short interest through 2025-10-31 · Stale
Short interest synced 2026-08-05T22:39:51.787625Z
News through 2026-07-31T13:20:00Z · Stale
News synced 2026-08-02T07:26:53.664136Z
Company profile: Delayed
Company profile synced 2026-05-06T21:55:58.178672Z
Regular-session price
Offline$141.11
+1.37% regular session
1Y Change
+21.16%
Window
Aug 5, 2025 → Aug 4, 2026
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
+1.4%
1M
+6.6%
6M
+4.7%
YTD
+0.9%
1Y
+21.2%
Coverage: 250 bars · Aug 5, 2025 → Aug 4, 2026
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
A is 1.67 pts behind over the shared 1Y window.
A had 20.74 pts deeper max drawdown than SPY.
A beat SPY in 1 of 2 calendar years shown and trailed in 1.
A
+21.16%
Normalized return
SPY
+22.83%
S&P 500
Excess Return
-1.67 pts
Relative to SPY
A Max Drawdown
-29.87%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for A and SPY.
| Year | A | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +0.91% | +12.67% | -11.77 pts | SPY |
| 2025 | +19.78% | +9.40% | +10.38 pts | A |
Financials
Annual, quarterly, and TTM views with reported currency, units, source, download, and filing context.
Period
Units
Reported currency
USD
Source
FMP
Last checked
Apr 7, 2026
FY Revenue
$6.9B
+6.7% YoY
FY Net Income
$1.3B
+1.1% YoY
Free Cash Flow
$1.2B
-16.1% YoY
Revenue Growth
+6.7%
EPS Growth
+3.4%
Gross Margin
52.4%
Net Margin
18.8%
Income statement
USD
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 6,319M | 6,848M | 6,833M | 6,510M | 6,948M |
| Gross Profit | 3,407M | 3,722M | 3,465M | 3,535M | 3,643M |
| Operating Income | 1,347M | 1,618M | 1,350M | 1,488M | 1,479M |
| EBITDA | 1,762M | 1,905M | 1,703M | 1,874M | 1,835M |
| Net Income | 1,210M | 1,254M | 1,240M | 1,289M | 1,303M |
| EPS (Diluted) | -- | -- | -- | -- | -- |
Balance sheet
USD
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1,484M | 1,053M | 1,590M | 1,329M | 1,789M |
| Total Assets | 10,705M | 10,532M | 10,763M | 11,846M | 12,727M |
| Total Liabilities | 5,316M | 5,227M | 4,918M | 5,948M | 5,986M |
| Shareholder Equity | 5,389M | 5,305M | 5,845M | 5,898M | 6,741M |
| Total Debt | 2,729M | 2,769M | 2,735M | 3,574M | 3,354M |
| Net Debt | 1,245M | 1,716M | 1,145M | 2,245M | 1,565M |
Cash flow positioning
2025
Operating Cash Flow
1,559M
-11.0% YoY
Capital Expenditures
407M
-7.7% YoY
Free Cash Flow
1,152M
-16.1% YoY
Key ratios
Gross Margin
52.4%
Operating Margin
21.3%
Net Margin
18.8%
ROE
19.7%
Debt / Equity
0.49x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.